Erin E Burke1, Schelomo Marmor1,2, Beth A Virnig2, Todd M Tuttle1, Eric H Jensen3. 1. Department of Surgery, University of Minnesota, 420 Delaware Street SE, Mayo Mail Code 195, Minneapolis, MN, 55455, USA. 2. School of Public Health, University of Minnesota, Minneapolis, MN, USA. 3. Department of Surgery, University of Minnesota, 420 Delaware Street SE, Mayo Mail Code 195, Minneapolis, MN, 55455, USA. jense893@umn.edu.
Abstract
BACKGROUND: Adequate lymph node evaluation (LNE) is recommended for surgically treated pancreatic adenocarcinoma because studies have shown an association between improved survival and adequate LNE. This study aimed to understand the mechanism of this association and determine whether LNE is a valuable quality metric. METHODS: Using the linked Surveillance Epidemiology End Results Medicare database, we identified patients with surgically treated pancreatic adenocarcinoma from 2000 to 2010. Adequate LNE was defined as evaluation of ≥15 nodes. Survival was determined using Kaplan-Meier and Cox proportional hazards. RESULTS: We identified 2629 patients who underwent resection for pancreatic adenocarcinoma. Overall, 33 % had adequate LNE. Adequate LNE was significantly associated with receipt of postoperative chemotherapy. A significant decrease in hazard of death was associated with adequate LNE (HR 0.86, p < 0.05). Receipt of postoperative chemotherapy was also significantly associated with decreased hazard of death (HR 0.77, p < 0.05). On unadjusted analysis, the survival benefit associated with adequate LNE was lost when stratified by receipt of postoperative chemotherapy. CONCLUSION: The survival benefit associated with LNE is in part derived from the fact that patients who receive adequate LNE are also more likely to receive chemotherapy. Thus, the use of lymph node counts has limitations as a quality metric.
BACKGROUND: Adequate lymph node evaluation (LNE) is recommended for surgically treated pancreatic adenocarcinoma because studies have shown an association between improved survival and adequate LNE. This study aimed to understand the mechanism of this association and determine whether LNE is a valuable quality metric. METHODS: Using the linked Surveillance Epidemiology End Results Medicare database, we identified patients with surgically treated pancreatic adenocarcinoma from 2000 to 2010. Adequate LNE was defined as evaluation of ≥15 nodes. Survival was determined using Kaplan-Meier and Cox proportional hazards. RESULTS: We identified 2629 patients who underwent resection for pancreatic adenocarcinoma. Overall, 33 % had adequate LNE. Adequate LNE was significantly associated with receipt of postoperative chemotherapy. A significant decrease in hazard of death was associated with adequate LNE (HR 0.86, p < 0.05). Receipt of postoperative chemotherapy was also significantly associated with decreased hazard of death (HR 0.77, p < 0.05). On unadjusted analysis, the survival benefit associated with adequate LNE was lost when stratified by receipt of postoperative chemotherapy. CONCLUSION: The survival benefit associated with LNE is in part derived from the fact that patients who receive adequate LNE are also more likely to receive chemotherapy. Thus, the use of lymph node counts has limitations as a quality metric.
Authors: Marianne Huebner; Michael Kendrick; Kaye M Reid-Lombardo; Florencia Que; Terry Therneau; Rui Qin; John Donohue; David Nagorney; Michael Farnell; Michael Sarr Journal: J Gastrointest Surg Date: 2012-03-16 Impact factor: 3.452
Authors: Eric A Mellon; Gregory M Springett; Sarah E Hoffe; Pamela Hodul; Mokenge P Malafa; Kenneth L Meredith; William J Fulp; Xiuhua Zhao; Ravi Shridhar Journal: Cancer Date: 2014-01-03 Impact factor: 6.860
Authors: Helen M Parsons; Todd M Tuttle; Karen M Kuntz; James W Begun; Patricia M McGovern; Beth A Virnig Journal: J Am Coll Surg Date: 2012-06-08 Impact factor: 6.113
Authors: Nakul P Valsangkar; Devon M Bush; James S Michaelson; Cristina R Ferrone; Jennifer A Wargo; Keith D Lillemoe; Carlos Fernández-del Castillo; Andrew L Warshaw; Sarah P Thayer Journal: J Gastrointest Surg Date: 2012-12-11 Impact factor: 3.452
Authors: Minia Hellan; Can-Lan Sun; Avo Artinyan; Pablo Mojica-Manosa; Smita Bhatia; Joshua D I Ellenhorn; Joseph Kim Journal: Pancreas Date: 2008-07 Impact factor: 3.327
Authors: Mark B Slidell; David C Chang; John L Cameron; Christopher Wolfgang; Joseph M Herman; Richard D Schulick; Michael A Choti; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2007-09-26 Impact factor: 5.344
Authors: Krisha J Opfermann; Amy E Wahlquist; Elizabeth Garrett-Mayer; Ravi Shridhar; Leander Cannick; David T Marshall Journal: Am J Clin Oncol Date: 2014-04 Impact factor: 2.339
Authors: Anand Govindarajan; Jensen C C Tan; Nancy N Baxter; Natalie G Coburn; Calvin H L Law Journal: Ann Surg Oncol Date: 2007-10-02 Impact factor: 5.344